Samsung Electronics Co., Ltd.

Washington University

Dennis W Choi

Jae-Young Koh

Sung-Bo Ko

Eu-Gene Oh

Laura L Dugan

Kyung-Hwa Kim

In-Jae Shin

Moo-Ho Won

Won-Yeob Kim

In-Kyu Chang

Laura Dugan

Tien-yau Luh

Tien-Sung Tom Lin

Sandra Jeanne Hewett

Tae-Cheon Kang

Kyung-Mi Kim

Eon-Kyeom Kim

Myung-Bok Wie

Novel dialkylhydroxybenzoic acid derivatives containing metal chelating groups are disclosed. The novel compounds are used as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species and/or excess Zn ions, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds have not only low toxicity but also similar or superior LPO inhibition activity to references. They also effectively inhibit the cerebral neuronal cell death by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.

Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses

The present invention provides novel dialkylhydroxybenzoic acid derivatives containing metal chelating groups and the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species and/or excess Zn ions, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds of the invention have not only low toxicity but also similar or superior LPO inhibition activity to references. They also effectively inhibit the cerebral neuronal cell death by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.

The present invention provides novel N-alkyl-N-phenylhydroxylamine derivatives containing metal chelating groups, a process for preparing the same, the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species (ROS) and/or excess Zn ions, in particular stroke, Parkinson's disease and Alzheimer's disease. The compounds of the invention possess similar or superior LPO inhibition activity to the reference compounds of Trolox and Ebselen. While showing lower toxicity, they also effectively inhibit the cerebral neuronal cell death caused by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.

N-alkyl-N-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses

The present invention provides novel seleno compounds containing nitrone moiety, a process for preparing the same, the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds of the invention have similar or superior lipid peroxidation (LPO) inhibition activity to the reference compounds. While showing lower toxicity and better water solubility, they also effectively inhibit the cerebral neuronal cell death caused by ROS and show neuroprotective effects against ischemic neuronal degeneration.

Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses

A method of treating neurotoxic injury, where the injury is the result of the release of oxygen-derived free radicals, is disclosed. The method utilizes carboxyfullerenes as free radicals scavengers to reduce the damage caused by the free radicals.

Method for treating neuronal injury with carboxyfullerene

A method of reducing neurotoxic injury due to acute or chronic neurological insults by administering an anthranilic acid derivative is disclosed.

Method of reducing glutamate neurotoxicity with anthranilic acid

Growing community of inventors

St. Louis, MO, United States of America

Dennis W Choi